NASDAQ:NAMS NewAmsterdam Pharma (NAMS) Stock Price, News & Analysis $32.48 +1.81 (+5.90%) Closing price 04:00 PM EasternExtended Trading$32.48 0.00 (0.00%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About NewAmsterdam Pharma Stock (NASDAQ:NAMS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NewAmsterdam Pharma alerts:Sign Up Key Stats Today's Range$31.00▼$34.6250-Day Range$21.28▼$32.4852-Week Range$14.06▼$34.62Volume2.20 million shsAverage Volume1.03 million shsMarket Capitalization$3.66 billionP/E RatioN/ADividend YieldN/APrice Target$42.00Consensus RatingModerate Buy Company Overview NewAmsterdam Pharma, Inc. is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism. The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation. These investigational compounds are designed to improve glycemic control, support weight management and reduce cardiometabolic risk factors. NewAmsterdam Pharma’s programs emphasize oral delivery formats and aim to provide differentiated safety and efficacy profiles compared with existing therapies. Headquartered in the United States, NewAmsterdam Pharma leverages a network of research collaborations with academic institutions and industry partners to accelerate its discovery and development activities. The company’s strategic alliances support advancement of its clinical candidates through regulatory milestones and position it to pursue global development and commercialization opportunities for patients with metabolic disorders.AI Generated. May Contain Errors. Read More NewAmsterdam Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreNAMS MarketRank™: NewAmsterdam Pharma scored higher than 59% of companies evaluated by MarketBeat, and ranked 438th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingNewAmsterdam Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 8 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialNewAmsterdam Pharma has a consensus price target of $42.00, representing about 29.3% upside from its current price of $32.48.Amount of Analyst CoverageNewAmsterdam Pharma has only been the subject of 4 research reports in the past 90 days.Read more about NewAmsterdam Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for NewAmsterdam Pharma are expected to decrease in the coming year, from ($1.75) to ($1.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NewAmsterdam Pharma is -20.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NewAmsterdam Pharma is -20.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNewAmsterdam Pharma has a P/B Ratio of 3.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about NewAmsterdam Pharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.50% of the float of NewAmsterdam Pharma has been sold short.Short Interest Ratio / Days to CoverNewAmsterdam Pharma has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in NewAmsterdam Pharma has recently increased by 12.40%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNewAmsterdam Pharma does not currently pay a dividend.Dividend GrowthNewAmsterdam Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.50% of the float of NewAmsterdam Pharma has been sold short.Short Interest Ratio / Days to CoverNewAmsterdam Pharma has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in NewAmsterdam Pharma has recently increased by 12.40%, indicating that investor sentiment is decreasing significantly. News and Social Media1.7 / 5News Sentiment0.10 News SentimentNewAmsterdam Pharma has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for NewAmsterdam Pharma this week, compared to 7 articles on an average week.Search InterestOnly 2 people have searched for NAMS on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows6 people have added NewAmsterdam Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership5.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, NewAmsterdam Pharma insiders have sold 13,327.54% more of their company's stock than they have bought. Specifically, they have bought $58,424.00 in company stock and sold $7,844,906.00 in company stock.Percentage Held by Insiders20.84% of the stock of NewAmsterdam Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.89% of the stock of NewAmsterdam Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NewAmsterdam Pharma's insider trading history. Receive NAMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NAMS Stock News HeadlinesNewAmsterdam Pharma (NASDAQ:NAMS) Director James Topper Buys 660 SharesSeptember 18, 2025 | insidertrades.comNewAmsterdam Pharma (NASDAQ:NAMS) Director Acquires $31,487.40 in StockSeptember 11, 2025 | insidertrades.comForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be the biggest paradigm shift ever. Yes, even bigger than AI. And he found one Seattle company that's at the center of this new $100 trillion revolution. Click here to get the name of this company, completely free of charge...October 6 at 2:00 AM | Brownstone Research (Ad)NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 18,073 SharesSeptember 6, 2025 | insidertrades.comAnalysts Set NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Price Target at $42.00September 30, 2025 | americanbankingnews.comNewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic ForumSeptember 24, 2025 | globenewswire.comNewAmsterdam Pharma Company N.V. (NAMS) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 3, 2025 | seekingalpha.comPiramal Pharma completes multimillion-dollar upgrade to Bucks County plantAugust 29, 2025 | bizjournals.comSee More Headlines NAMS Stock Analysis - Frequently Asked Questions How have NAMS shares performed this year? NewAmsterdam Pharma's stock was trading at $25.70 at the beginning of 2025. Since then, NAMS stock has increased by 26.4% and is now trading at $32.48. How were NewAmsterdam Pharma's earnings last quarter? NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) posted its quarterly earnings results on Wednesday, August, 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.52) by $0.37. The business had revenue of $19.15 million for the quarter, compared to the consensus estimate of $1.44 million. NewAmsterdam Pharma had a negative trailing twelve-month return on equity of 27.27% and a negative net margin of 259.07%. How do I buy shares of NewAmsterdam Pharma? Shares of NAMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NewAmsterdam Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that NewAmsterdam Pharma investors own include Nextera Energy Partners (NEP), Enterprise Products Partners (EPD), Blue Owl Capital (OBDC), Pimco Corporate & Income Opportunity Fund (PTY), PayPal (PYPL) and Ventyx Biosciences (VTYX). Company Calendar Last Earnings8/06/2025Today10/06/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NAMS CIK1936258 Webwww.newamsterdampharma.com Phone352062971FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Price Target for NewAmsterdam Pharma$42.00 High Price Target$52.00 Low Price Target$27.00 Potential Upside/Downside+28.6%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($1.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$241.60 million Net Margins-259.07% Pretax Margin-258.91% Return on Equity-27.27% Return on Assets-25.00% Debt Debt-to-Equity RatioN/A Current Ratio21.08 Quick Ratio21.08 Sales & Book Value Annual Sales$64.01 million Price / Sales57.45 Cash FlowN/A Price / Cash FlowN/A Book Value$8.20 per share Price / Book3.98Miscellaneous Outstanding Shares112,628,000Free Float89,156,000Market Cap$3.68 billion OptionableOptionable Beta0.02 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:NAMS) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredIs This Warren’s Buffett’s #1 AI Investment?Did you know that Warren Buffett is investing in what Jeff Brown believes will be the next generation of artif...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Company N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.